Shiga toxins as multi-functional proteins: Induction of host cellular stress responses, role in pathogenesis and therapeutic applications

Toxins

Volumn 8, Issue 3, 2016, Pages

  Lee, Moo Seung ^a   Koo, Sunwoo ^b   Jeong, Dae Gwin ^a   Tesh, Vernon L ^c  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b TEXAS A M COLLEGE OF MEDICINE   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

Cancer therapeutics; Hemolytic uremic syndrome; Shiga toxin type 1 and 2; Shiga toxin producing Escherichia coli; Shiga toxins; Signaling pathways

Indexed keywords

GLUCOSE REGULATED PROTEIN 78; GLYCOGEN SYNTHASE KINASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN KINASE B; PROTEIN KINASE R; PROTEIN SYNTHESIS INHIBITOR; SHIGA TOXIN; STRESS ACTIVATED PROTEIN KINASE 1; TUMOR NECROSIS FACTOR ALPHA; VEROTOXIN 1; VEROTOXIN 2; ANTINEOPLASTIC AGENT;

APOPTOSIS; AUTOPHAGY; BINDING AFFINITY; BIOENGINEERING; CANCER THERAPY; CELLULAR STRESS RESPONSE; CENTRAL NERVOUS SYSTEM DISEASE; CRYSTAL STRUCTURE; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION; HEMOLYTIC UREMIC SYNDROME; INFLAMMATION; INNATE IMMUNITY; INTRACELLULAR TRANSPORT; NONHUMAN; PATHOGENESIS; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; RECEPTOR BINDING; REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SHIGELLA DYSENTERIAE; TUNEL ASSAY; UNFOLDED PROTEIN RESPONSE; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; PHYSIOLOGICAL STRESS; PROTEIN CONFORMATION; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN CONFORMATION; PROTEIN SYNTHESIS INHIBITORS; SHIGA TOXINS; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL;

EID: 84962606370     PISSN: None     EISSN: 20726651     Source Type: Journal    
DOI: 10.3390/toxins8030077     Document Type: Review

References (188)

1. Trofa, A.F, Ueno-Olsen, H, Oiwa, R, Yoshikawa, M. Kiyoshi Shiga: Discoverer of the dysentery bacillus. Clin. Infect. Dis. 1999, 29, 1303-1306. [CrossRef] [PubMed]
2. O’Brien, A.D, LaVeck, G.D, Griffin, D.E, Thompson, M.R. Characterization of Shigella dysenteriae 1 (Shiga) toxin purified by anti-Shiga toxin affinity chromatography. Infect. Immun. 1980, 30, 170-179. [PubMed]
3. Olsnes, S, Eiklid, K. Isolation and characterization of Shigella shigae cytotoxin. J. Biol. Chem. 1980, 255, 284-289. [PubMed]
4. Konowalchuk, J, Speirs, J.I, Stavric, S. Vero response to a cytotoxin of Escherichia coli. Infect. Immun. 1977, 18, 775-779. [PubMed]
5. O’Brien, A.D, Lively, T.A, Chen, M.E, Rothman, S.W, Formal, S.B. Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (Shiga) like cytotoxin. Lancet 1983, 1, 702. [CrossRef]
6. Mora, A, Herrera, A, Lopez, C, Dahbi, G, Mamani, R, Pita, J.M, Alonso, M.P, Llovo, J, Bernardez, M.I, Blanco, J.E, et al. Characteristics of the Shiga-toxin-producing enteroaggregative Escherichia coli O104:H4 German outbreak strain and of STEC strains isolated in Spain. Int. Microbiol. 2011, 14, 121-141. [PubMed]
7. Kaper, J.B, O’Brien, A.D. Overview and historical perspectives. Microbiol. Spectr. 2014, 2. [CrossRef]
8. Proulx, F, Tesh, V.L. Renal diseases in the pediatric intensive care unit: Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenia purpura. In Pediatric Care Medicine: Basic Science and Clinical Evidence; Wheeler, D.S.,Wong, H.R., Shanley, T.P., Eds, Springer-Verlag: London, UK, 2007; pp. 1189-1203.
9. Gould, L.H, Demma, L, Jones, T.F, Hurd, S, Vugia, D.J, Smith, K, Shiferaw, B, Segler, S, Palmer, A, Zansky, S, et al. Hemolytic uremic syndrome and death in persons with Escherichia coli O157:H7 infection, foodborne diseases active surveillance network sites, 2000-2006. Clin. Infect. Dis. 2009, 49, 1480-1485. [CrossRef] [PubMed]
10. Tarr, P.I, Gordon, C.A, Chandler, W.L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005, 365, 1073-1086. [CrossRef]
11. Tarr, P.I. Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Distinct mechanisms of pathogenesis. Kidney Int. Suppl. 2009, S29-S32. [CrossRef] [PubMed]
12. Mayer, C.L, Leibowitz, C.S, Kurosawa, S, Stearns-Kurosawa, D.J. Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals. Toxins 2012, 4, 1261-1287. [CrossRef] [PubMed]
13. Gyles, C.L. Shiga toxin-producing Escherichia coli: An overview. J. Anim. Sci. 2007, 85, E45-E62. [CrossRef] [PubMed]
14. Erickson, M.C, Doyle, M.P. Food as a vehicle for transmission of Shiga toxin-producing Escherichia coli. J. Food Prot. 2007, 70, 2426-2449. [PubMed]
15. Rangel, J.M, Sparling, P.H, Crowe, C, Griffin, P.M, Swerdlow, D.L. Epidemiology of Escherichia coli O157:H7 outbreaks, United States, 1982-2002. Emerg. Infect. Dis. 2005, 11, 603-609. [CrossRef] [PubMed]
16. Mead, P.S, Slutsker, L, Dietz, V, McCaig, L.F, Bresee, J.S, Shapiro, C, Griffin, P.M, Tauxe, R.V. Food-related illness and death in the United States. Emerg. Infect. Dis. 1999, 5, 607-625. [CrossRef] [PubMed]
17. Scallan, E, Mahon, B.E, Hoekstra, R.M, Griffin, P.M. Estimates of illnesses, hospitalizations and deaths caused by major bacterial enteric pathogens in young children in the United States. Pediatr. Infect. Dis. J. 2013, 32, 217-221. [CrossRef] [PubMed]
18. Buchholz, U, Bernard, H, Werber, D, Bohmer, M.M, Remschmidt, C, Wilking, H, Delere, Y, an der Heiden, M, Adlhoch, C, Dreesman, J, et al. German outbreak of Escherichia coli O104:H4 associated with sprouts. N. Engl. J. Med. 2011, 365, 1763-1770. [CrossRef] [PubMed]
19. Bielaszewska, M, Mellmann, A, Zhang, W, Kock, R, Fruth, A, Bauwens, A, Peters, G, Karch, H. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: A microbiological study. Lancet Infect. Dis. 2011, 11, 671-676. [CrossRef]
20. Frenzen, P.D, Drake, A, Angulo, F.J, Emerging Infections Program FoodNetWorking Group. Economic cost of illness due to Escherichia coli O157 infections in the United States. J. Food Prot. 2005, 68, 2623-2630. [PubMed]
21. Kotloff, K.L, Winickoff, J.P, Ivanoff, B, Clemens, J.D, Swerdlow, D.L, Sansonetti, P.J, Adak, G.K, Levine, M.M. Global burden of Shigella infections: Implications for vaccine development and implementation of control strategies. Bull. World Health Organ. 1999, 77, 651-666. [PubMed]
22. Nicolas, X, Granier, H, le Guen, P. Shigellosis or bacillary dysentery. Presse Med. 2007, 36, 1606-1618. [CrossRef] [PubMed]
23. Tilden, J., Jr., Young, W, McNamara, A.M, Custer, C, Boesel, B, Lambert-Fair, M.A, Majkowski, J, Vugia, D, Werner, S.B, Hollingsworth, J, et al. A new route of transmission for Escherichia coli: Infection from dry fermented salami. Am. J. Public Health 1996, 86, 1142-1145. [CrossRef] [PubMed]
24. DuPont, H.L, Levine, M.M, Hornick, R.B, Formal, S.B. Inoculum size in shigellosis and implications for expected mode of tranmission. J. Infect. Dis. 1989, 159, 1126-1128. [CrossRef] [PubMed]
25. Scheutz, F, Teel, L.D, Beutin, L, Pierard, D, Buvens, G, Karch, H, Mellmann, A, Caprioli, A, Tozzoli, R, Morabito, S, et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. J. Clin. Microbiol. 2012, 50, 2951-2963. [CrossRef] [PubMed]
26. Strockbine, N.A, Marques, L.R, Newland, J.W, Smith, H.W, Holmes, R.K, O’Brien, A.D. Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect. Immun. 1986, 53, 135-140. [PubMed]
27. Thorpe, C.M, Hurley, B.P, Acheson, D.W. Shiga toxin interactions with the intestinal epithelium. Methods Mol. Med. 2003, 73, 263-273. [PubMed]
28. Schuller, S. Shiga toxin interaction with human intestinal epithelium. Toxins 2011, 3, 626-639. [CrossRef] [PubMed]
29. Brigotti, M, Carnicelli, D, Ravanelli, E, Barbieri, S, Ricci, F, Bontadini, A, Tozzi, A.E, Scavia, G, Caprioli, A, Tazzari, P.L. Interactions between Shiga toxins and human polymorphonuclear leukocytes. J. Leukoc. Biol. 2008, 84, 1019-1027. [CrossRef] [PubMed]
30. Brigotti, M, Tazzari, P.L, Ravanelli, E, Carnicelli, D, Barbieri, S, Rocchi, L, Arfilli, V, Scavia, G, Ricci, F, Bontadini, A, et al. Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration. J. Leukoc. Biol. 2010, 88, 201-210. [CrossRef] [PubMed]
31. Patzelt, W.J. Reflexion contrast, a new microscopic technic. Naturwissenschaften 1976, 63, 535. [CrossRef] [PubMed]
32. Ståhl, A.L, Sartz, L, Karpman, D. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 2011, 117, 5503-5513. [CrossRef] [PubMed]
33. Ge, S, Hertel, B, Emden, S.H, Beneke, J, Menne, J, Haller, H, von Vietinghoff, S. Microparticle generation and leucocyte death in Shiga toxin-mediated HUS. Nephrol. Dial. Transpl. 2012, 27, 2768-2775. [CrossRef] [PubMed]
34. Ståhl, A.L, Arvidsson, I, Johansson, K.E, Chromek, M, Rebetz, J, Loos, S, Kristoffersson, A.C, Bekassy, Z.D, Morgelin, M, Karpman, D. A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles. PLoS Pathog. 2015, 11, e1004619. [CrossRef] [PubMed]
35. Boyd, B, Lingwood, C. Verotoxin receptor glycolipid in human renal tissue. Nephron 1989, 51, 207-210. [CrossRef] [PubMed]
36. Sandvig, K, Bergan, J, Kavaliauskiene, S, Skotland, T. Lipid requirements for entry of protein toxins into cells. Prog. Lipid Res. 2014, 54, 1-13. [CrossRef] [PubMed]
37. Romer, W, Berland, L, Chambon, V, Gaus, K, Windschiegl, B, Tenza, D, Aly, M.R, Fraisier, V, Florent, J.C, Perrais, D, et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature 2007, 450, 670-675. [CrossRef] [PubMed]
38. Sandvig, K, Garred, O, Prydz, K, Kozlov, J.V, Hansen, S.H, van Deurs, B. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature 1992, 358, 510-512. [CrossRef] [PubMed]
39. Garred, O, van Deurs, B, Sandvig, K. Furin-induced cleavage and activation of Shiga toxin. J. Biol. Chem. 1995, 270, 10817-10821. [PubMed]
40. Garred, O, Dubinina, E, Polesskaya, A, Olsnes, S, Kozlov, J, Sandvig, K. Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells. J. Biol. Chem. 1997, 272, 11414-11419. [PubMed]
41. Garred, O, Dubinina, E, Holm, P.K, Olsnes, S, van Deurs, B, Kozlov, J.V, Sandvig, K. Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants. Exp. Cell Res. 1995, 218, 39-49. [CrossRef] [PubMed]
42. LaPointe, P, Wei, X, Gariepy, J. A role for the protease-sensitive loop region of Shiga-like toxin 1 in the retrotranslocation of itsA1 domain fromthe endoplasmic reticulumlumen. J. Biol. Chem. 2005, 280, 23310-23318. [CrossRef] [PubMed]
43. Yu, M, Haslam, D.B. Shiga toxin is transported from the endoplasmic reticulum following interaction with the luminal chaperone HEDJ/ERdj3. Infect. Immun. 2005, 73, 2524-2532. [CrossRef] [PubMed]
44. Falguieres, T, Johannes, L. Shiga toxin B-subunit binds to the chaperone BiP and the nucleolar protein B23. Biol. Cell 2006, 98, 125-134. [CrossRef] [PubMed]
45. Tam, P.J, Lingwood, C.A. Membrane cytosolic translocation of verotoxin A1 subunit in target cells. Microbiology 2007, 153, 2700-2710. [CrossRef] [PubMed]
46. Menikh, A, Saleh, M.T, Gariepy, J, Boggs, J.M. Orientation in lipid bilayers of a synthetic peptide representing the C-terminus of the A1 domain of Shiga toxin. A polarized ATR-FTIR study. Biochemistry 1997, 36, 15865-15872. [CrossRef] [PubMed]
47. Saleh, M.T, Ferguson, J, Boggs, J.M, Gariepy, J. Insertion and orientation of a synthetic peptide representing the C-terminus of the A1 domain of Shiga toxin into phospholipid membranes. Biochemistry 1996, 35, 9325-9334. [CrossRef] [PubMed]
48. Spooner, R.A, Lord, J.M. How ricin and Shiga toxin reach the cytosol of target cells: Retrotranslocation from the endoplasmic reticulum. Curr. Top. Microbiol. Immunol. 2012, 357, 19-40. [PubMed]
49. Hazes, B, Read, R.J. Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells. Biochemistry 1997, 36, 11051-11054. [CrossRef] [PubMed]
50. Johannes, L, Romer, W. Shiga toxins-from cell biology to biomedical applications. Nat. Rev. Microbiol. 2010, 8, 105-116. [CrossRef] [PubMed]
51. Janssen, K.P, Vignjevic, D, Boisgard, R, Falguieres, T, Bousquet, G, Decaudin, D, Dolle, F, Louvard, D, Tavitian, B, Robine, S, et al. In vivo tumor targeting using a novel intestinal pathogen-based delivery approach. Cancer Res 2006, 66, 7230-7236. [CrossRef] [PubMed]
52. Distler, U, Souady, J, Hulsewig, M, Drmic-Hofman, I, Haier, J, Friedrich, A.W, Karch, H, Senninger, N, Dreisewerd, K, Berkenkamp, S, et al. Shiga toxin receptor Gb3Cer/CD77: Tumor-association and promising therapeutic target in pancreas and colon cancer. PLoS ONE 2009, 4, e6813. [CrossRef] [PubMed]
53. Farkas-Himsley, H, Hill, R, Rosen, B, Arab, S, Lingwood, C.A. The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc. Natl. Acad. Sci. USA 1995, 92, 6996-7000. [CrossRef] [PubMed]
54. Maak, M, Nitsche, U, Keller, L, Wolf, P, Sarr, M, Thiebaud, M, Rosenberg, R, Langer, R, Kleeff, J, Friess, H, et al. Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit. Mol. Cancer Ther. 2011, 10, 1918-1928. [CrossRef] [PubMed]
55. Fraser, M.E, Fujinaga, M, Cherney, M.M, Melton-Celsa, A.R, Twiddy, E.M, O’Brien, A.D, James, M.N. Structure of Shiga toxin type 2 (Stx2) from Escherichia coli O157:H7. J. Biol. Chem. 2004, 279, 27511-27517. [CrossRef] [PubMed]
56. Fraser, M.E, Chernaia, M.M, Kozlov, Y.V, James, M.N. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 Å resolution. Nat. Struct. Biol. 1994, 1, 59-64. [CrossRef] [PubMed]
57. Sandvig, K. Shiga toxins. Toxicon 2001, 39, 1629-1635. [CrossRef]
58. Beddoe, T, Paton, A.W, le Nours, J, Rossjohn, J, Paton, J.C. Structure, biological functions and applications of the AB5 toxins. Trends Biochem. Sci. 2010, 35, 411-418. [CrossRef] [PubMed]
59. Merritt, E.A, Pronk, S.E, Sixma, T.K, Kalk, K.H, van Zanten, B.A, Hol,W.G. Structure of partially-activated E. coli heat-labile enterotoxin (LT) at 2.6 Å resolution. FEBS Lett. 1994, 337, 88-92. [CrossRef]
60. Endo, Y, Tsurugi, K, Yutsudo, T, Takeda, Y, Ogasawara, T, Igarashi, K. Site of action of a vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 1988, 171, 45-50. [CrossRef] [PubMed]
61. Saxena, S.K, Ackerman, E.J. Microinjected oligonucleotides complementary to the alpha-sarcin loop of 28 S RNA abolish protein synthesis in Xenopus oocytes. J. Biol. Chem. 1990, 265, 3263-3269. [PubMed]
62. Hovde, C.J, Calderwood, S.B, Mekalanos, J.J, Collier, R.J. Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I. Proc. Natl. Acad. Sci. USA 1988, 85, 2568-2572. [CrossRef] [PubMed]
63. Fraser, M.E, Cherney, M.M, Marcato, P, Mulvey, G.L, Armstrong, G.D, James, M.N. Binding of adenine to Stx2, the protein toxin from Escherichia coli O157:H7. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2006, 62, 627-630. [CrossRef] [PubMed]
64. Lingwood, C.A. Shiga toxin receptor glycolipid binding. Pathology and utility. Methods Mol. Med. 2003, 73, 165-186. [PubMed]
65. Nakajima, H, Kiyokawa, N, Katagiri, Y.U, Taguchi, T, Suzuki, T, Sekino, T, Mimori, K, Ebata, T, Saito, M, Nakao, H, et al. Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J. Biol. Chem. 2001, 276, 42915-42922. [CrossRef] [PubMed]
66. Gallegos, K.M, Conrady, D.G, Karve, S.S, Gunasekera, T.S, Herr, A.B, Weiss, A.A. Shiga toxin binding to glycolipids and glycans. PLoS ONE 2012, 7, e30368. [CrossRef] [PubMed]
67. Brigotti, M, Carnicelli, D, Arfilli, V, Tamassia, N, Borsetti, F, Fabbri, E, Tazzari, P.L, Ricci, F, Pagliaro, P, Spisni, E, et al. Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils. J. Immunol. 2013, 191, 4748-4758. [CrossRef] [PubMed]
68. Waddell, T, Cohen, A, Lingwood, C.A. Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc. Natl. Acad. Sci. USA 1990, 87, 7898-7901. [CrossRef] [PubMed]
69. Ling, H, Boodhoo, A, Hazes, B, Cummings, M.D, Armstrong, G.D, Brunton, J.L, Read, R.J. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 1998, 37, 1777-1788. [CrossRef] [PubMed]
70. St Hilaire, P.M, Boyd, M.K, Toone, E.J. Interaction of the Shiga-like toxin type 1 B-subunit with its carbohydrate receptor. Biochemistry 1994, 33, 14452-14463. [CrossRef] [PubMed]
71. Stein, P.E, Boodhoo, A, Tyrrell, G.J, Brunton, J.L, Read, R.J. Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli. Nature 1992, 355, 748-750. [CrossRef] [PubMed]
72. Shimizu, H, Field, R.A, Homans, S.W, Donohue-Rolfe, A. Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry 1998, 37, 11078-11082. [CrossRef] [PubMed]
73. Bast, D.J, Banerjee, L, Clark, C, Read, R.J, Brunton, J.L. The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the verotoxin 1 B subunit. Mol. Microbiol. 1999, 32, 953-960. [CrossRef] [PubMed]
74. Kitova, E.N, Kitov, P.I, Paszkiewicz, E, Kim, J, Mulvey, G.L, Armstrong, G.D, Bundle, D.R, Klassen, J.S. Affinities of Shiga toxins 1 and 2 for univalent and oligovalent pk-trisaccharide analogs measured by electrospray ionization mass spectrometry. Glycobiology 2007, 17, 1127-1137. [CrossRef] [PubMed]
75. Fuchs, G, Mobassaleh, M, Donohue-Rolfe, A, Montgomery, R.K, Grand, R.J, Keusch, G.T. Pathogenesis of Shigella diarrhea: Rabbit intestinal cell microvillus membrane binding site for Shigella toxin. Infect. Immun. 1986, 53, 372-377. [PubMed]
76. Jacobson, J.M, Yin, J, Kitov, P.I, Mulvey, G, Griener, T.P, James, M.N, Armstrong, G, Bundle, D.R. The crystal structure of Shiga toxin type 2 with bound disaccharide guides the design of a heterobifunctional toxin inhibitor. J. Biol. Chem. 2014, 289, 885-894. [CrossRef] [PubMed]
77. Conrady, D.G, Flagler, M.J, Friedmann, D.R, Vander Wielen, B.D, Kovall, R.A, Weiss, A.A, Herr, A.B. Molecular basis of differential B-pentamer stability of Shiga toxins 1 and 2. PLoS ONE 2010, 5, e15153. [CrossRef] [PubMed]
78. Karve, S.S, Weiss, A.A. Glycolipid binding preferences of Shiga toxin variants. PLoS ONE 2014, 9, e101173. [CrossRef] [PubMed]
79. Bergan, J, Dyve Lingelem, A.B, Simm, R, Skotland, T, Sandvig, K. Shiga toxins. Toxicon 2012, 60, 1085-1107. [CrossRef] [PubMed]
80. Malyukova, I, Murray, K.F, Zhu, C, Boedeker, E, Kane, A, Patterson, K, Peterson, J.R, Donowitz, M, Kovbasnjuk, O. Macropinocytosis in Shiga toxin 1 uptake by human intestinal epithelial cells and transcellular transcytosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 296, G78-G92. [CrossRef] [PubMed]
81. Johannes, L, Decaudin, D. Protein toxins: Intracellular trafficking for targeted therapy. Gene Ther. 2005, 12, 1360-1368. [CrossRef]
82. Engedal, N, Skotland, T, Torgersen, M, Sandvig, K. Shiga toxin and its use in targeted cancer therapy and imaging. Microb. Biotechnol. 2011, 4, 32-46. [CrossRef] [PubMed]
83. Stimmer, L, Dehay, S, Nemati, F, Massonnet, G, Richon, S, Decaudin, D, Klijanienko, J, Johannes, L. Human breast cancer and lymph node metastases express Gb3 and can be targeted by StxB-vectorized chemotherapeutic compounds. BMC Cancer 2014, 14. [CrossRef] [PubMed]
84. Roberts, L.M, Lord, J.M. Ribosome-inactivating proteins: Entry into mammalian cells and intracellular routing. Mini Rev. Med. Chem. 2004, 4, 505-512. [CrossRef] [PubMed]
85. Iordanov, M.S, Pribnow, D, Magun, J.L, Dinh, T.H, Pearson, J.A, Chen, S.L, Magun, B.E. Ribotoxic stress response: Activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the -sarcin/ricin loop in the 28S rRNA. Mol. Cell. Biol. 1997, 17, 3373-3381. [CrossRef] [PubMed]
86. Cherla, R.P, Lee, S.Y, Mees, P.L, Tesh, V.L. Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line. J. Leukoc. Biol. 2006, 79, 397-407. [CrossRef] [PubMed]
87. Foster, G.H, Tesh, V.L. Shiga toxin 1-induced activation of c-Jun NH2-terminal kinase and p38 in the human monocytic cell line THP-1: Possible involvement in the production of TNF-. J. Leukoc. Biol. 2002, 71, 107-114. [PubMed]
88. Smith, W.E, Kane, A.V, Campbell, S.T, Acheson, D.W, Cochran, B.H, Thorpe, C.M. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. Infect. Immun. 2003, 71, 1497-1504. [CrossRef] [PubMed]
89. Nallagatla, S.R, Toroney, R, Bevilacqua, P.C. Regulation of innate immunity through RNA structure and the protein kinase PKR. Curr. Opin. Struct. Biol. 2011, 21, 119-127. [CrossRef] [PubMed]
90. Zhou, H.R, Lau, A.S, Pestka, J.J. Role of double-stranded RNA-activated protein kinase R (PKR) in deoxynivalenol-induced ribotoxic stress response. Toxicol. Sci. 2003, 74, 335-344. [CrossRef] [PubMed]
91. Bae, H, Gray, J.S, Li, M, Vines, L, Kim, J, Pestka, J.J. Hematopoietic cell kinase associates with the 40S ribosomal subunit and mediates the ribotoxic stress response to deoxynivalenol in mononuclear phagocytes. Toxicol. Sci. 2010, 115, 444-452. [CrossRef] [PubMed]
92. Zhang, P, Langland, J.O, Jacobs, B.L, Samuel, C.E. Protein kinase PKR-dependent activation of mitogen-activated protein kinases occurs through mitochondrial adapter IPS-1 and is antagonized by vaccinia virus E3L. J. Virol. 2009, 83, 5718-5725. [CrossRef] [PubMed]
93. Jandhyala, D.M, Ahluwalia, A, Obrig, T, Thorpe, C.M. ZAK: A MAP3Kinase that transduces Shiga toxin- and ricin-induced proinflammatory cytokine expression. Cell. Microbiol. 2008, 10, 1468-1477. [CrossRef] [PubMed]
94. Garibal, J, Hollville, E, Renouf, B, Tetaud, C, Wiels, J. Caspase-8-mediated cleavage of Bid and protein phosphatase 2a-mediated activation of Bax are necessary for verotoxin-1-induced apoptosis in Burkitt’s lymphoma cells. Cell. Signal. 2010, 22, 467-475. [CrossRef] [PubMed]
95. Ellgaard, L, Helenius, A. Quality control in the endoplasmic reticulum. Nat. Rev. Mol. Cell Biol. 2003, 4, 181-191. [CrossRef] [PubMed]
96. Ron, D, Walter, P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat. Rev. Mol. Cell Biol. 2007, 8, 519-529. [CrossRef] [PubMed]
97. Hetz, C. The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 2012, 13, 89-102. [CrossRef] [PubMed]
98. Szegezdi, E, Logue, S.E, Gorman, A.M, Samali, A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 2006, 7, 880-885. [CrossRef] [PubMed]
99. Kadowaki, H, Nishitoh, H, Ichijo, H. Survival and apoptosis signals in ER stress: The role of protein kinases. J. Chem. Neuroanat. 2004, 28, 93-100. [CrossRef] [PubMed]
100. Joyce, M.A, Walters, K.A, Lamb, S.E, Yeh, M.M, Zhu, L.F, Kneteman, N, Doyle, J.S, Katze, M.G, Tyrrell, D.L. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathog. 2009, 5, e1000291. [CrossRef] [PubMed]
101. Chan, S.W. Unfolded protein response in Hepatitis C Virus infection. Front. Microbiol. 2014, 5. [CrossRef] [PubMed]
102. Celli, J, Tsolis, R.M. Bacteria, the endoplasmic reticulum and the unfolded protein response: Friends or foes? Nat. Rev. Microbiol. 2015, 13, 71-82. [CrossRef] [PubMed]
103. Lee, S.Y, Lee, M.S, Cherla, R.P, Tesh, V.L. Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells. Cell. Microbiol. 2008, 10, 770-780. [CrossRef] [PubMed]
104. Lentz, E.K, Leyva-Illades, D, Lee, M.S, Cherla, R.P, Tesh, V.L. Differential response of the human renal proximal tubular epithelial cell line HK-2 to Shiga toxin types 1 and 2. Infect. Immun. 2011, 79, 3527-3540. [CrossRef] [PubMed]
105. Parello, C.S, Mayer, C.L, Lee, B.C, Motomochi, A, Kurosawa, S, Stearns-Kurosawa, D.J. Shiga toxin 2-induced endoplasmic reticulum stress is minimized by activated protein C but does not correlate with lethal kidney injury. Toxins 2015, 7, 170-186. [CrossRef] [PubMed]
106. Tang, B, Li, Q, Zhao, X.H, Wang, H.G, Li, N, Fang, Y, Wang, K, Jia, Y.P, Zhu, P, Gu, J, et al. Shiga toxins induce autophagic cell death in intestinal epithelial cells via the endoplasmic reticulum stress pathway. Autophagy 2015, 11, 344-354. [CrossRef] [PubMed]
107. Mele, C, Remuzzi, G, Noris, M. Hemolytic uremic syndrome. Semin. Immunopathol. 2014, 36, 399-420. [CrossRef] [PubMed]
108. Inward, C.D, Williams, J, Chant, I, Crocker, J, Milford, D.V, Rose, P.E, Taylor, C.M. Verocytotoxin-1 induces apoptosis in Vero cells. J. Infect. 1995, 30, 213-218. [CrossRef]
109. Karpman, D, Hakansson, A, Perez, M.T, Isaksson, C, Carlemalm, E, Caprioli, A, Svanborg, C. Apoptosis of renal cortical cells in the hemolytic-uremic syndrome: In vivo and in vitro studies. Infect. Immun. 1998, 66, 636-644. [PubMed]
110. Te Loo, D.M, Monnens, L.A, van derVelden, T.J, Vermeer, M.A, Preyers, F, Demacker, P.N, van denHeuvel, L.P, van Hinsbergh, V.W. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 2000, 95, 3396-3402. [PubMed]
111. Lee, M.S, Cherla, R.P, Leyva-Illades, D, Tesh, V.L. Bcl-2 regulates the onset of Shiga toxin 1-induced apoptosis in THP-1 cells. Infect. Immun. 2009, 77, 5233-5244. [CrossRef] [PubMed]
112. Ito, T, Deng, X, Carr, B, May, W.S. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 1997, 272, 11671-11673. [CrossRef] [PubMed]
113. Deng, X, Xiao, L, Lang, W, Gao, F, Ruvolo, P, May, W.S., Jr. Novel role for JNK as a stress-activated Bcl2 kinase. J. Biol. Chem. 2001, 276, 23681-23688. [CrossRef] [PubMed]
114. Lee, M.S, Cherla, R.P, Lentz, E.K, Leyva-Illades, D, Tesh, V.L. Signaling through C/EBP homologous protein and death receptor 5 and calpain activation differentially regulate THP-1 cell maturation-dependent apoptosis induced by Shiga toxin type 1. Infect. Immun. 2010, 78, 3378-3391. [CrossRef] [PubMed]
115. Ikeda, M, Gunji, Y, Sonoda, H, Oshikawa, S, Shimono, M, Horie, A, Ito, K, Yamasaki, S. Inhibitory effect of tyrphostin 47 on Shiga toxin-induced cell death. Eur. J. Pharmacol. 2006, 546, 36-39. [CrossRef] [PubMed]
116. Jones, N.L, Islur, A, Haq, R, Mascarenhas, M, Karmali, M.A, Perdue, M.H, Zanke, B.W, Sherman, P.M. Escherichia coli Shiga toxins induce apoptosis in epithelial cells that is regulated by the BCL-2 family. Am. J. Physiol. Gastrointest. Liver Physiol. 2000, 278, G811-G819. [PubMed]
117. Fujii, J, Matsui, T, Heatherly, D.P, Schlegel, K.H, Lobo, P.I, Yutsudo, T, Ciraolo, G.M, Morris, R.E, Obrig, T. Rapid apoptosis induced by Shiga toxin in HeLa cells. Infect. Immun. 2003, 71, 2724-2735. [CrossRef] [PubMed]
118. Erwert, R.D, Eiting, K.T, Tupper, J.C, Winn, R.K, Harlan, J.M, Bannerman, D.D. Shiga toxin induces decreased expression of the anti-apoptotic protein Mcl-1 concomitant with the onset of endothelial apoptosis. Microb. Pathog. 2003, 35, 87-93. [CrossRef]
119. Kiyokawa, N, Mori, T, Taguchi, T, Saito, M, Mimori, K, Suzuki, T, Sekino, T, Sato, N, Nakajima, H, Katagiri, Y.U, et al. Activation of the caspase cascade during Stx1-induced apoptosis in Burkitt’s lymphoma cells. J. Cell. Biochem. 2001, 81, 128-142. [CrossRef]
120. Mangeney, M, Lingwood, C.A, Taga, S, Caillou, B, Tursz, T, Wiels, J. Apoptosis induced in Burkitt’s lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res. 1993, 53, 5314-5319. [PubMed]
121. Tetaud, C, Falguieres, T, Carlier, K, Lecluse, Y, Garibal, J, Coulaud, D, Busson, P, Steffensen, R, Clausen, H, Johannes, L, et al. Two distinct Gb3/CD77 signaling pathways leading to apoptosis are triggered by anti-Gb3/CD77 mab and verotoxin-1. J. Biol. Chem. 2003, 278, 45200-45208. [CrossRef] [PubMed]
122. Kaneko, K, Kiyokawa, N, Ohtomo, Y, Nagaoka, R, Yamashiro, Y, Taguchi, T, Mori, T, Fujimoto, J, Takeda, T. Apoptosis of renal tubular cells in Shiga-toxin-mediated hemolytic uremic syndrome. Nephron 2001, 87, 182-185. [CrossRef] [PubMed]
123. Te Loo, D.M, Monnens, L.A, van den Heuvel, L.P, Gubler, M.C, Kockx, M.M. Detection of apoptosis in kidney biopsies of patients with D+ hemolytic uremic syndrome. Pediatr. Res. 2001, 49, 413-416. [CrossRef] [PubMed]
124. Psotka, M.A, Obata, F, Kolling, G.L, Gross, L.K, Saleem, M.A, Satchell, S.C, Mathieson, P.W, Obrig, T.G. Shiga toxin 2 targets the murine renal collecting duct epithelium. Infect. Immun. 2009, 77, 959-969. [CrossRef] [PubMed]
125. DesRochers, T.M, Kimmerling, E.P, Jandhyala, D.M, El-Jouni, W, Zhou, J, Thorpe, C.M, Leong, J.M, Kaplan, D.L. Effects of Shiga toxin type 2 on a bioengineered three-dimensional model of human renal tissue. Infect. Immun. 2015, 83, 28-38. [CrossRef] [PubMed]
126. Takahashi, K, Funata, N, Ikuta, F, Sato, S. Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2. J. Neuroinflamm. 2008, 5. [CrossRef] [PubMed]
127. Tesh, V.L. The induction of apoptosis by Shiga toxins and ricin. Curr. Top. Microbiol. Immunol. 2012, 357, 137-178. [PubMed]
128. Maiuri, M.C, Zalckvar, E, Kimchi, A, Kroemer, G. Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat. Rev. Mol. Cell Biol. 2007, 8, 741-752. [CrossRef] [PubMed]
129. Chaabane, W, User, S.D, El-Gazzah, M, Jaksik, R, Sajjadi, E, Rzeszowska-Wolny, J, Los, M.J. Autophagy, apoptosis, mitoptosis and necrosis: Interdependence between those pathways and effects on cancer. Arch. Immunol. Ther. Exp. 2013, 61, 43-58. [CrossRef] [PubMed]
130. Moretti, L, Cha, Y.I, Niermann, K.J, Lu, B. Switch between apoptosis and autophagy: Radiation-induced endoplasmic reticulum stress? Cell Cycle 2007, 6, 793-798. [CrossRef] [PubMed]
131. Wu, H, Che, X, Zheng, Q, Wu, A, Pan, K, Shao, A, Wu, Q, Zhang, J, Hong, Y. Caspases: A molecular switch node in the crosstalk between autophagy and apoptosis. Int. J. Biol. Sci. 2014, 10, 1072-1083. [CrossRef] [PubMed]
132. Booth, L.A, Tavallai, S, Hamed, H.A, Cruickshanks, N, Dent, P. The role of cell signalling in the crosstalk between autophagy and apoptosis. Cell. Signal. 2014, 26, 549-555. [CrossRef] [PubMed]
133. Sandvig, K, van Deurs, B. Toxin-induced cell lysis: Protection by 3-methyladenine and cycloheximide. Exp. Cell Res. 1992, 200, 253-262. [CrossRef]
134. Lee, M.S, Cherla, R.P, Jenson, M.H, Leyva-Illades, D, Martinez-Moczygemba, M, Tesh, V.L. Shiga toxins induce autophagy leading to differential signalling pathways in toxin-sensitive and toxin-resistant human cells. Cell. Microbiol. 2011, 13, 1479-1496. [CrossRef] [PubMed]
135. Weston, R.T, Puthalakath, H. Endoplasmic reticulum stress and BCL-2 family members. Adv. Exp. Med. Biol. 2010, 687, 65-77. [PubMed]
136. Hoyer-Hansen, M, Jaattela, M. Connecting endoplasmic reticulum stress to autophagy by unfolded protein response and calcium. Cell Death Differ. 2007, 14, 1576-1582. [CrossRef] [PubMed]
137. Leyva-Illades, D, Cherla, R.P, Lee, M.S, Tesh, V.L. Regulation of cytokine and chemokine expression by the ribotoxic stress response elicited by Shiga toxin type 1 in human macrophage-like THP-1 cells. Infect. Immun. 2012, 80, 2109-2120. [CrossRef] [PubMed]
138. Tesh, V.L. Shiga toxins—Not just cytotoxins anymore. Trends Microbiol. 2001, 9, 584-585. [CrossRef]
139. Foster, G.H, Armstrong, C.S, Sakiri, R, Tesh, V.L. Shiga toxin-induced tumor necrosis factor alpha expression: Requirement for toxin enzymatic activity and monocyte protein kinase C and protein tyrosine kinases. Infect. Immun. 2000, 68, 5183-5189. [CrossRef] [PubMed]
140. Broggi, A, Granucci, F. Microbe- and danger-induced inflammation. Mol. Immunol. 2015, 63, 127-133. [CrossRef] [PubMed]
141. Wiersinga, W.J, Leopold, S.J, Cranendonk, D.R, van der Poll, T. Host innate immune responses to sepsis. Virulence 2014, 5, 36-44. [CrossRef] [PubMed]
142. Girardis, M, Cossarizza, A. Early alterations of B cells in patients with septic shock: Another piece in the complex puzzle of the immune response in sepsis. Crit. Care 2013, 17. [CrossRef] [PubMed]
143. Gustot, T. Multiple organ failure in sepsis: Prognosis and role of systemic inflammatory response. Curr. Opin. Crit. Care 2011, 17, 153-159. [CrossRef] [PubMed]
144. Van de Kar, N.C, Monnens, L.A, Karmali, M.A, van Hinsbergh, V.W. Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: Implications for the pathogenesis of the hemolytic uremic syndrome. Blood 1992, 80, 2755-2764. [PubMed]
145. Ramegowda, B, Samuel, J.E, Tesh, V.L. Interaction of Shiga toxins with human brain microvascular endothelial cells: Cytokines as sensitizing agents. J. Infect. Dis. 1999, 180, 1205-1213. [CrossRef] [PubMed]
146. Stricklett, P.K, Hughes, A.K, Ergonul, Z, Kohan, D.E. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. J. Infect. Dis. 2002, 186, 976-982. [CrossRef] [PubMed]
147. Raqib, R, Wretlind, B, Andersson, J, Lindberg, A.A. Cytokine secretion in acute shigellosis is correlated to disease activity and directed more to stool than to plasma. J. Infect. Dis. 1995, 171, 376-384. [CrossRef] [PubMed]
148. Yamamoto, T, Nagayama, K, Satomura, K, Honda, T, Okada, S. Increased serum IL-10 and endothelin levels in hemolytic uremic syndrome caused by Escherichia coli O157. Nephron 2000, 84, 326-332. [CrossRef] [PubMed]
149. Harrison, L.M, van Haaften, W.C, Tesh, V.L. Regulation of proinflammatory cytokine expression by Shiga toxin 1 and/or lipopolysaccharides in the human monocytic cell line THP-1. Infect. Immun. 2004, 72, 2618-2627. [CrossRef] [PubMed]
150. Harrison, L.M, van den Hoogen, C, van Haaften, W.C.E, Tesh, V.L. Chemokine expression in the monocytic cell line THP-1 in response to purified Shiga toxin 1 and/or lipopolysaccharides. Infect. Immun. 2005, 73, 403-412. [CrossRef] [PubMed]
151. Harrison, L.M, Cherla, R.P, van den Hoogen, C, van Haaften, W.C, Lee, S.Y, Tesh, V.L. Comparative evaluation of apoptosis induced by Shiga toxin 1 and/or lipopolysaccharides in human monocytic and macrophage-like cells. Microb. Pathog. 2005, 38, 63-76. [CrossRef] [PubMed]
152. Van Setten, P.A, Monnens, L.A, Verstraten, R.G, van den Heuvel, L.P, van Hinsbergh, V.W. Effects of verocytotoxin-1 on nonadherent human monocytes: Binding characteristics, protein synthesis, and induction of cytokine release. Blood 1996, 88, 174-183. [PubMed]
153. Falguieres, T, Mallard, F, Baron, C, Hanau, D, Lingwood, C, Goud, B, Salamero, J, Johannes, L. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol. Biol. Cell 2001, 12, 2453-2468. [CrossRef] [PubMed]
154. Ramegowda, B, Tesh, V.L. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in humanmonocytes andmonocytic cell lines. Infect. Immun. 1996, 64, 1173-1180. [PubMed]
155. Smith, D.C, Sillence, D.J, Falguieres, T, Jarvis, R.M, Johannes, L, Lord, J.M, Platt, F.M, Roberts, L.M. The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol. Biol. Cell 2006, 17, 1375-1387. [CrossRef] [PubMed]
156. Murata, K, Higuchi, T, Takada, K, Oida, K, Horie, S, Ishii, H. Verotoxin-1 stimulation of macrophage-like THP-1 cells up-regulates tissue factor expression through activation of c-Yes tyrosine kinase: Possible signal transduction in tissue factor up-regulation. Biochim. Biophys. Acta 2006, 1762, 835-843. [CrossRef] [PubMed]
157. Lee, M.S, Kwon, H, Lee, E.Y, Kim, D.J, Park, J.H, Tesh, V.L, Oh, T.K, Kim, M.H. Shiga toxins activate the NLRP3 inflammasome pathway to promote both production of the proinflammatory cytokine interleukin-1 and apoptotic cell death. Infect. Immun. 2016, 84, 172-186. [CrossRef] [PubMed]
158. Philpott, D.J, Ackerley, C.A, Kiliaan, A.J, Karmali, M.A, Perdue, M.H, Sherman, P.M. Translocation of verotoxin-1 across T84 monolayers: Mechanism of bacterial toxin penetration of epithelium. Am. J. Physiol. 1997, 273, G1349-G1358. [PubMed]
159. Bellmeyer, A, Cotton, C, Kanteti, R, Koutsouris, A, Viswanathan, V.K, Hecht, G. Enterohemorrhagic Escherichia coli suppresses inflammatory response to cytokines and its own toxin. Am. J. Physiol. Gastrointest. Liver Physiol. 2009, 297, G576-G581. [CrossRef] [PubMed]
160. Jandhyala, D.M, Rogers, T.J, Kane, A, Paton, A.W, Paton, J.C, Thorpe, C.M. Shiga toxin 2 and flagellin from Shiga-toxigenic Escherichia coli superinduce interleukin-8 through synergistic effects on host stress-activated protein kinase activation. Infect. Immun. 2010, 78, 2984-2994. [CrossRef] [PubMed]
161. Miyamoto, Y, Iimura, M, Kaper, J.B, Torres, A.G, Kagnoff, M.F. Role of Shiga toxin versus H7 flagellin in enterohaemorrhagic Escherichia coli signalling of human colon epithelium in vivo. Cell. Microbiol. 2006, 8, 869-879. [CrossRef] [PubMed]
162. Keepers, T.R, Gross, L.K, Obrig, T.G. Monocyte chemoattractant protein 1, macrophage inflammatory protein 1 alpha, and RANTES recruit macrophages to the kidney in a mouse model of hemolytic-uremic syndrome. Infect. Immun. 2007, 75, 1229-1236. [CrossRef] [PubMed]
163. Stearns-Kurosawa, D.J, Collins, V, Freeman, S, Tesh, V.L, Kurosawa, S. Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli. Infect. Immun. 2010, 78, 2497-2504. [CrossRef] [PubMed]
164. Stearns-Kurosawa, D.J, Oh, S.Y, Cherla, R.P, Lee, M.S, Tesh, V.L, Papin, J, Henderson, J, Kurosawa, S. Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli Shiga toxins in non-human primate models of hemolytic uremic syndrome. Am. J. Pathol. 2013, 182, 1227-1238. [CrossRef] [PubMed]
165. Cherla, R.P, Lee, S.Y, Mulder, R.A, Lee, M.S, Tesh, V.L. Shiga toxin 1-induced proinflammatory cytokine production is regulated by the Phosphatidylinositol 3-kinase/Akt/Mammalian Target of Rapamycin signaling pathway. Infect. Immun. 2009, 77, 3919-3931. [CrossRef] [PubMed]
166. Lentz, E.K, Cherla, R.P, Jaspers, V, Weeks, B.R, Tesh, V.L. Role of tumor necrosis factor alpha in disease using a mouse model of Shiga toxin-mediated renal damage. Infect. Immun. 2010, 78, 3689-3699. [CrossRef] [PubMed]
167. Ergonul, Z, Hughes, A.K, Kohan, D.E. Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin 1. J. Infect. Dis. 2003, 187, 154-158. [CrossRef] [PubMed]
168. Hagel, C, Krasemann, S, Loffler, J, Puschel, K, Magnus, T, Glatzel, M. Upregulation of Shiga toxin receptor CD77/Gb3 and interleukin-1beta expression in the brain of EHEC patients with hemolytic uremic syndrome and neurologic symptoms. Brain Pathol. 2015, 25, 146-156. [CrossRef] [PubMed]
169. Landoni, V.I, Schierloh, P, de Campos Nebel, M, Fernandez, G.C, Calatayud, C, Lapponi, M.J, Isturiz, M.A. Shiga toxin 1 induces on lipopolysaccharide-treated astrocytes the release of tumor necrosis factor-alpha that alter brain-like endothelium integrity. PLoS Pathog. 2012, 8, e1002632. [CrossRef] [PubMed]
170. Van Setten, P.A, van Hinsbergh, V.W, van der Velden, T.J, van de Kar, N.C, Vermeer, M, Mahan, J.D, Assmann, K.J, van den Heuvel, L.P, Monnens, L.A. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. Kidney Int. 1997, 51, 1245-1256. [CrossRef] [PubMed]
171. Eisenhauer, P.B, Jacewicz, M.S, Conn, K.J, Koul, O, Wells, J.M, Fine, R.E, Newburg, D.S. Escherichia coli Shiga toxin 1 and TNF-alpha induce cytokine release by human cerebral microvascular endothelial cells. Microb. Pathog. 2004, 36, 189-196. [CrossRef] [PubMed]
172. Lee, M.S, Kim, M.H, Tesh, V.L. Shiga toxins expressed by human pathogenic bacteria induce immune responses in host cells. J. Microbiol. 2013, 51, 724-730. [CrossRef] [PubMed]
173. Kovbasnjuk, O, Mourtazina, R, Baibakov, B, Wang, T, Elowsky, C, Choti, M.A, Kane, A, Donowitz, M. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. Proc. Natl. Acad. Sci. USA 2005, 102, 19087-19092. [CrossRef] [PubMed]
174. Falguieres, T, Maak, M, von Weyhern, C, Sarr, M, Sastre, X, Poupon, M.F, Robine, S, Johannes, L, Janssen, K.P. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol. Cancer Ther. 2008, 7, 2498-2508. [CrossRef] [PubMed]
175. LaCasse, E.C, Bray, M.R, Patterson, B, Lim, W.M, Perampalam, S, Radvanyi, L.G, Keating, A, Stewart, A.K, Buckstein, R, Sandhu, J.S, et al. Shiga-like toxin-1 receptor on human breast cancer, lymphoma, and myeloma and absence from CD34(+) hematopoietic stem cells: Implications for ex vivo tumor purging and autologous stem cell transplantation. Blood 1999, 94, 2901-2910. [PubMed]
176. Johansson, D, Kosovac, E, Moharer, J, Ljuslinder, I, Brannstrom, T, Johansson, A, Behnam-Motlagh, P. Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis. BMC Cancer 2009, 9. [CrossRef] [PubMed]
177. Sandstrom, M, Johansson, M, Bergstrom, P, Bergenheim, A.T, Henriksson, R. Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. J. Neurooncol. 2008, 88, 1-9. [CrossRef] [PubMed]
178. Heath-Engel, H.M, Lingwood, C.A. Verotoxin sensitivity of ECV304 cells in vitro and in vivo in a xenograft tumour model: VT1 as a tumour neovascular marker. Angiogenesis 2003, 6, 129-141. [CrossRef] [PubMed]
179. Salhia, B, Rutka, J.T, Lingwood, C, Nutikka, A, van Furth, W.R. The treatment of malignant meningioma with verotoxin. Neoplasia 2002, 4, 304-311. [CrossRef] [PubMed]
180. Ishitoya, S, Kurazono, H, Nishiyama, H, Nakamura, E, Kamoto, T, Habuchi, T, Terai, A, Ogawa, O, Yamamoto, S. Verotoxin induces rapid elimination of human renal tumor xenografts in scid mice. J. Urol. 2004, 171, 1309-1313. [CrossRef] [PubMed]
181. Arab, S, Rutka, J, Lingwood, C. Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice. Oncol. Res. 1999, 11, 33-39. [PubMed]
182. Amessou, M, Carrez, D, Patin, D, Sarr, M, Grierson, D.S, Croisy, A, Tedesco, A.C, Maillard, P, Johannes, L. Retrograde delivery of photosensitizer (TPPp-O-GluOH)3 selectively potentiates its photodynamic activity. Bioconj. Chem. 2008, 19, 532-538. [CrossRef] [PubMed]
183. El Alaoui, A, Schmidt, F, Amessou, M, Sarr, M, Decaudin, D, Florent, J.C, Johannes, L. Shiga toxin-mediated retrograde delivery of a topoisomerase I inhibitor prodrug. Angew. Chem. Int. Ed. Engl. 2007, 46, 6469-6472. [CrossRef] [PubMed]
184. Batisse, C, Dransart, E, Ait Sarkouh, R, Brulle, L, Bai, S.K, Godefroy, S, Johannes, L, Schmidt, F. A new delivery system for auristatin in StxB-drug conjugate therapy. Eur. J. Med. Chem. 2015, 95, 483-491. [CrossRef] [PubMed]
185. Viel, T, Dransart, E, Nemati, F, Henry, E, Theze, B, Decaudin, D, Lewandowski, D, Boisgard, R, Johannes, L, Tavitian, B. In vivo tumor targeting by the B-subunit of Shiga toxin. Mol. Imaging 2008, 7, 239-247. [PubMed]
186. Qin, S, Caskey, C.F, Ferrara, K.W. Ultrasound contrast microbubbles in imaging and therapy: Physical principles and engineering. Phys. Med. Biol. 2009, 54, R27-R57. [CrossRef] [PubMed]
187. Couture, O, Dransart, E, Dehay, S, Nemati, F, Decaudin, D, Johannes, L, Tanter, M. Tumor delivery of ultrasound contrast agents using Shiga toxin B subunit. Mol. Imaging 2011, 10, 135-143. [PubMed]
188. Bray, M.R, Bisland, S, Perampalam, S, Lim, W.M, Gariepy, J. Probing the surface of eukaryotic cells using combinatorial toxin libraries. Curr. Biol. 2001, 11, 697-701. [CrossRef]